Budesonide/Formoterol Teva Pharma B.V.

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Download Risalah maklumat (PIL)
08-12-2021
Download Ciri produk (SPC)
08-12-2021
Download Laporan Penilaian Awam (PAR)
01-01-1970

Bahan aktif:

Budesonide, formoterol fumarate dihydrate

Boleh didapati daripada:

Teva Pharma B.V. 

Kod ATC:

R03AK07

INN (Nama Antarabangsa):

budesonide, formoterol fumarate dihydrate

Kumpulan terapeutik:

Drugs for obstructive airway diseases,

Kawasan terapeutik:

Asthma; Pulmonary Disease, Chronic Obstructive

Tanda-tanda terapeutik:

Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) 

Ringkasan produk:

Revision: 2

Status kebenaran:

Authorised

Tarikh kebenaran:

2020-04-03

Risalah maklumat

                                47
B. PACKAGE LEAFLET
48
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. 160 MICROGRAMS/4.5 MICROGRAMS,
INHALATION POWDER
budesonide/formoterol fumarate dihydrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Budesonide/Formoterol Teva Pharma B.V. is and what it is used for
2.
What you need to know before you use Budesonide/Formoterol Teva Pharma
B.V.
3.
How to use Budesonide/Formoterol Teva Pharma B.V.
4.
Possible side effects
5.
How to store Budesonide/Formoterol Teva Pharma B.V.
6.
Contents of the pack and other information
1.
WHAT BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS AND WHAT IT IS USED FOR
Budesonide/Formoterol Teva Pharma B.V. contains two different active
substances: budesonide and
formoterol fumarate dihydrate.
•
Budesonide belongs to a group of medicines called
‘corticosteroids’ also known as ‘steroids’. It
works by reducing and preventing swelling and inflammation in your
lungs and helps you to
breathe more easily.
•
Formoterol fumarate dihydrate belongs to a group of medicines called
‘long-acting β
2
adrenoceptor agonists’ or ‘bronchodilators’. It works by
relaxing the muscles in your airways.
This will help to open the airways and help you to breathe more
easily.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS INDICATED FOR USE IN ADULTS
18 YEARS OF AGE AND
OLDER ONLY.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS NOT INDICATED FOR USE IN
CHILDREN 12 YEARS OF AGE
AND YOUNGER OR ADOLESCENTS 13 TO 17 YEARS OF AGE.
Your 
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms
inhalation powder
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece of the
Spiromax) contains 160 micrograms
of budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
This is equivalent to a metered dose of 200 micrograms budesonide and
6 micrograms of formoterol
fumarate dihydrate.
Excipient(s) with known effect:
Each dose contains approximately 5 milligrams of lactose (as
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder.
White powder.
White inhaler with a semi-transparent wine red mouthpiece cover.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years
of age and older only.
Asthma
_ _
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular
treatment of asthma, where use
of a combination (inhaled corticosteroid and long-acting β
2
adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids
and “as needed” inhaled short-acting
β
2
adrenoceptor agonists.
or
-in patients already adequately controlled on both inhaled
corticosteroids and long-acting β
2
adrenoceptor agonists.
COPD
_ _
Symptomatic treatment of patients with COPD with forced expiratory
volume in 1 second
(FEV
1
) < 70% predicted normal (post bronchodilator) and a history of
repeated exacerbations, who
have significant symptoms despite regular therapy with long-acting
bronchodilators.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Asthma _
_ _
Budesonide/Formoterol Teva Pharma B.V. is not intended for the initial
management of asthma.
Budesonide/Formoterol Teva Pharma B.V. is not an appropriate treatment
for the adult patient with
only mild asthma who is not adequately controlled with an inhaled
corticosteroid and “as needed”
inhaled short-acting β

                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 08-12-2021
Ciri produk Ciri produk Bulgaria 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 01-01-1970
Risalah maklumat Risalah maklumat Sepanyol 08-12-2021
Ciri produk Ciri produk Sepanyol 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 01-01-1970
Risalah maklumat Risalah maklumat Czech 08-12-2021
Ciri produk Ciri produk Czech 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 01-01-1970
Risalah maklumat Risalah maklumat Denmark 08-12-2021
Ciri produk Ciri produk Denmark 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 01-01-1970
Risalah maklumat Risalah maklumat Jerman 08-12-2021
Ciri produk Ciri produk Jerman 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 01-01-1970
Risalah maklumat Risalah maklumat Estonia 08-12-2021
Ciri produk Ciri produk Estonia 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 01-01-1970
Risalah maklumat Risalah maklumat Greek 08-12-2021
Ciri produk Ciri produk Greek 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 01-01-1970
Risalah maklumat Risalah maklumat Perancis 08-12-2021
Ciri produk Ciri produk Perancis 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 01-01-1970
Risalah maklumat Risalah maklumat Itali 08-12-2021
Ciri produk Ciri produk Itali 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 01-01-1970
Risalah maklumat Risalah maklumat Latvia 08-12-2021
Ciri produk Ciri produk Latvia 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 01-01-1970
Risalah maklumat Risalah maklumat Lithuania 08-12-2021
Ciri produk Ciri produk Lithuania 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 01-01-1970
Risalah maklumat Risalah maklumat Hungary 08-12-2021
Ciri produk Ciri produk Hungary 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 01-01-1970
Risalah maklumat Risalah maklumat Malta 08-12-2021
Ciri produk Ciri produk Malta 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 01-01-1970
Risalah maklumat Risalah maklumat Belanda 08-12-2021
Ciri produk Ciri produk Belanda 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 01-01-1970
Risalah maklumat Risalah maklumat Poland 08-12-2021
Ciri produk Ciri produk Poland 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 01-01-1970
Risalah maklumat Risalah maklumat Portugis 08-12-2021
Ciri produk Ciri produk Portugis 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 01-01-1970
Risalah maklumat Risalah maklumat Romania 08-12-2021
Ciri produk Ciri produk Romania 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 01-01-1970
Risalah maklumat Risalah maklumat Slovak 08-12-2021
Ciri produk Ciri produk Slovak 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 01-01-1970
Risalah maklumat Risalah maklumat Slovenia 08-12-2021
Ciri produk Ciri produk Slovenia 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 01-01-1970
Risalah maklumat Risalah maklumat Finland 08-12-2021
Ciri produk Ciri produk Finland 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 01-01-1970
Risalah maklumat Risalah maklumat Sweden 08-12-2021
Ciri produk Ciri produk Sweden 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 01-01-1970
Risalah maklumat Risalah maklumat Norway 08-12-2021
Ciri produk Ciri produk Norway 08-12-2021
Risalah maklumat Risalah maklumat Iceland 08-12-2021
Ciri produk Ciri produk Iceland 08-12-2021
Risalah maklumat Risalah maklumat Croat 08-12-2021
Ciri produk Ciri produk Croat 08-12-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 01-01-1970